Eisai US

There’s a transformation happening in the Alzheimer's disease (AD) treatment landscape, offering newfound hope to many. As we conclude #AlzheimersAwarenessMonth, I’ve been reflecting on what leading the charge against this progressive, debilitating disease has looked like lately at Eisai—coming on the heels of recent AD regulatory milestones and scientific advancements—and what the future of new data and research can bring. At the forefront of this progress are critical studies and deep insights stemming from Eisai US’s guiding philosophy: human health care (hhc). The hhc mission is the shared purpose that connects us to those we serve - to better understand the unmet needs of the community and shaping our approach to AD research and development. I’m proud of the work we’re doing to turn human-centered, scientifically proven insights into action. Read more about our patient-centered approach to advancing AD research: https://lnkd.in/e6s6e3KY

With data shared at ESMO and IGCS, we’re proud to have contributed to an impactful six weeks with our global oncology colleagues in endometrial cancer research and beyond. From Berlin's broad oncology discussions to Cape Town's specialized gynecologic cancer focus, these meetings reinforced the power of scientific collaboration. We were honored to share our long-term research findings with colleagues dedicated to improving patient outcomes. These gatherings remind us why we do this work – every collaboration brings us closer to making a meaningful difference for patients and their families.

We believe that every great advancement starts with human connection. Our refreshed corporate website highlights our commitment to human health care and the impact we’re making to help improve the lives of patients.

We’re excited to announce the launch of our revamped corporate website! This new layout is designed to highlight our commitment to pursuing breakthrough solutions in neurology and oncology.

The 2025 ESMO Congress brings together researchers, clinicians, and advocates dedicated to transforming cancer care. We look forward to presenting clinical data, including in endometrial carcinoma and renal cell carcinoma, in Berlin. Our research portfolio includes long-term follow-up insights and innovative therapeutic approaches. We're excited to contribute to the scientific dialogue that drives progress for patients worldwide. Rooted in our human health care philosophy, everything we do centers on working to improve outcomes for those who need it most.